Taiwan · Delayed Price · Currency is TWD CHO Pharma Statistics
Total Valuation
CHO Pharma has a market cap or net worth of TWD 21.83 billion. The enterprise value is 19.88 billion.
| Market Cap | 21.83B |
| Enterprise Value | 19.88B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHO Pharma has 214.01 million shares outstanding.
| Current Share Class | 214.01M |
| Shares Outstanding | 214.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 18.49% |
| Owned by Institutions (%) | 16.84% |
| Float | 143.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12,802.97 |
| PB Ratio | 9.20 |
| P/TBV Ratio | 11.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.96, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.96 |
| Quick Ratio | 21.32 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,121.52 |
Financial Efficiency
Return on equity (ROE) is -10.71% and return on invested capital (ROIC) is -7.49%.
| Return on Equity (ROE) | -10.71% |
| Return on Assets (ROA) | -7.24% |
| Return on Invested Capital (ROIC) | -7.49% |
| Return on Capital Employed (ROCE) | -12.71% |
| Weighted Average Cost of Capital (WACC) | 8.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 47 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +175.33% in the last 52 weeks. The beta is 0.76, so CHO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +175.33% |
| 50-Day Moving Average | 116.67 |
| 200-Day Moving Average | 60.36 |
| Relative Strength Index (RSI) | 38.23 |
| Average Volume (20 Days) | 428,155 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHO Pharma had revenue of TWD 1.71 million and -268.04 million in losses. Loss per share was -1.26.
| Revenue | 1.71M |
| Gross Profit | 1.15M |
| Operating Income | -301.69M |
| Pretax Income | -268.04M |
| Net Income | -268.04M |
| EBITDA | -292.21M |
| EBIT | -301.69M |
| Loss Per Share | -1.26 |
Balance Sheet
The company has 1.96 billion in cash and 7.33 million in debt, with a net cash position of 1.95 billion or 9.13 per share.
| Cash & Cash Equivalents | 1.96B |
| Total Debt | 7.33M |
| Net Cash | 1.95B |
| Net Cash Per Share | 9.13 |
| Equity (Book Value) | 2.37B |
| Book Value Per Share | 11.09 |
| Working Capital | 1.93B |
Cash Flow
In the last 12 months, operating cash flow was -241.25 million and capital expenditures -8.53 million, giving a free cash flow of -249.78 million.
| Operating Cash Flow | -241.25M |
| Capital Expenditures | -8.53M |
| Depreciation & Amortization | 9.48M |
| Net Borrowing | -14.45M |
| Free Cash Flow | -249.78M |
| FCF Per Share | -1.17 |
Margins
| Gross Margin | 67.45% |
| Operating Margin | -17,694.31% |
| Pretax Margin | -15,720.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHO Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.23% |
| FCF Yield | -1.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHO Pharma has an Altman Z-Score of 57.36 and a Piotroski F-Score of 3.
| Altman Z-Score | 57.36 |
| Piotroski F-Score | 3 |